Company Filing History:
Years Active: 2023-2024
Title: Innovations by Gary Luehr in the Treatment of Hyperkalemia
Introduction
Gary Luehr is an accomplished inventor based in Fremont, CA (US). He has made significant contributions to the field of medicine, particularly in the treatment of hyperkalemia. With a total of 2 patents, Luehr's work focuses on innovative compounds that can effectively manage this condition.
Latest Patents
Luehr's latest patents include "Glycyrrhetinic acid derivatives for use in treating hyperkalemia." This invention provides a compound of formula (I) or a salt thereof, wherein specific variables are defined. The claimed compounds inhibit the enzyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD2). As a result, they are useful in treating hyperkalemia by preventing cortisol from being oxidized to cortisone, thus allowing it to occupy the mineralocorticoid receptor and stimulating potassium excretion. Another patent, "Glycyrrhetinic acid derivatives for treating hyperkalemia," also presents a compound of formula (I) or a salt thereof, which serves a similar purpose in managing this medical condition.
Career Highlights
Gary Luehr is currently associated with Ardelyx, Inc., where he continues to develop innovative solutions for health challenges. His work has been instrumental in advancing treatments that address critical medical needs.
Collaborations
Luehr has collaborated with notable colleagues, including Dean R Dragoli and Tao Chen. Their combined expertise contributes to the success of their projects and innovations.
Conclusion
Gary Luehr's contributions to the field of medicine through his patents on glycyrrhetinic acid derivatives highlight his commitment to improving treatment options for hyperkalemia. His work exemplifies the impact of innovation in healthcare.